BridgeBio Pharma Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −8.52%.
Did BBIO Beat Earnings? Q4 2025 Results
BridgeBio Pharma delivered a mixed Q4 2025 report, posting revenue of $154.18 million against a consensus estimate of $149.64 million, a 3.03% beat, while its loss per share of $1.00 fell short of the $0.72 consensus by 39.66%, reflecting the heavy investment costs of building a commercial-stage biotech. The standout driver was Attruby, its ATTR-CM stabilizer approved in late 2024, which generated $146.02 million in net product revenue during the quarter, a 35% sequential jump fueled by rapidly expanding prescriber adoption. Revenue surged 2521.2% year-over-year as the company transitioned from development-stage to commercial operations, though operating losses of $139.56 million and non-cash royalty interest expense of $125.14 million for the full year remain significant headwinds. Analysts have taken notice, with multiple Wall Street firms raising price targets following the print. Looking ahead, BridgeBio plans NDA submissions for BBP-418 and encaleret in the first half of 2026 and is targeting what could be a six-approved-medicine portfolio, a <a href="https://247wallst.com/investing/2026/02/05/bristol-myers-just-crushed-earnings-and-the-real-catalyst-hasnt-even-hit-yet/">rare feat for emerging biotechs</a> of its scale.
- Attruby delivered 35% quarter-over-quarter growth in net product revenue in Q4 driven by differentiated clinical profile as only near-complete (≥90%) TTR stabilizer
- Continued prescribing growth with 7,804 unique patient prescriptions by 1,856 unique prescribers as of February 20, 2026
- Patient persistence exceeded company expectations
- Repeat prescriber use contributing to growth
- Royalty revenue increase from BEYONTTRA net product sales in EU and Japan
“As we close our first decade at BridgeBio, we're reflecting on just how far we've come – from a bold idea about a new type of biotech rooted in a hub-and-spoke model to a company with incredible commercial strength and multiple late-stage successes. In a little over three months, we've delivered three successful Phase 3 readouts, a testament to the rigor of our science, the dedication of our teams, and the trust of the patients and physicians we serve. In all, we hope this leads to 6 approved products as our first decade draws to a close. I am excited not only to live up to our responsibilities against these assets but further to see if we can do even better.”
BridgeBio Pharma CEO, on the earnings call
Forward Guidance & Outlook
BridgeBio plans NDA submissions for BBP-418 (LGMD2I/R9) and encaleret (ADH1) in 1H 2026 with U.S. launches anticipated in late 2026/early 2027. Infigratinib NDA for achondroplasia is planned for 2H 2026 with a launch in early to mid 2027. The company plans to initiate RECLAIM-HP, a Phase 3 study of encaleret in chronic hypoparathyroidism in 2H 2026, and accelerate infigratinib development for hypochondroplasia with Phase 2 data expected in 2H 2026. If successful, BridgeBio aims to have six approved medicines. The company is also pursuing regulatory paths in Europe for BBP-418 and infigratinib. The $632.5 million in 2033 convertible notes issued in January 2026 positions the company to fund planned commercial and pipeline operations.
BBIO YoY Financials
BBIO Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.